Immunocore Ready For First-Ever Launch After Kimmtrak’s US Approval
European Approval And Launch Also Expected Soon
The median pre-discount cost of Kimmtrak – the first approved TCR therapy and the first drug cleared for metastatic uveal melanoma – is $430,000, but the company says payers see the product’s value.
